The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The Society of Hematologic Oncology (SOHO) created the Young Investigator Program (YIP) to support the training and development of young investigators and to promote quality research in the field of hematologic oncology.
In this video interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Asfand Yar Cheema, MD, resident physician at Cleveland Clinic Fairview Hospital, discusses his SOHO 2025 abstract in patients with polycythemia vera who received GLP-1a therapy.
The commercial launch of a new blood cancer test for patients with B- and T-cell lymphomas took place during the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, Texas. The manufacturer of the test, Arima Genomics, hopes that the test will help guide clinicians to a clearer diagnosis.
In this video interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Reem Karmali, MD, an associate professor of medicine at Northwestern University, discusses the phase 2 TRANSCEND FL study.
About 8% of patients with the slow-growing Waldenström macroglobulinemia (WM) died from cardiovascular diseases – not their cancer – between 1999-2000, raising questions about the need for treatment of these comorbidities, according to a population study based on U.S. Centers for Disease Control and Prevention (CDC) data.
Patients with polycythemia vera (PV) who received GLP-1a therapy had markedly better outcomes than patients who did not, according to a retrospective study presented at the Thirteenth Annual Meeting of the Society of Hematologic Oncology.
An ongoing phase 1 study observed an 86% overall response rate (ORR) in patients with multiple myeloma (MM) treated with the novel trispecific antibody JNJ-5322.
In addition to death and taxes, no academic faculty member can escape the judgment of the dreaded Appointment and Promotions (A&P) Committee. In this (mostly) lighthearted perspective for SOHO Insider, Jerry Radich and Ted Gooley of Fred Hutchinson Cancer Center propose a new baseball-inspired formula for judging their peers.
A phase 1b/2 study added the investigational BCL-2 inhibitor lisaftoclax to pomalidomide/dexamethasone (Pd) and daratumumab/lenalidomide/dexamethasone (DRd) regimens and observed improved outcomes in patients with relapsed or refractory multiple myeloma (MM) and AL amyloidosis.
Achievement of early measurable residual disease (MRD) negativity under assessment with next-generation sequencing (NGS) is associated with durable remissions in patients with newly diagnosed Philadelphia-chromosome negative (Ph−) B-cell acute lymphoblastic leukemia (ALL), according to a new retrospective study.
